How to appeal an Aetna compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics

Cited policy: Aetna Medical Necessity Review on Compounded Drugs (and applicable Aetna Pharmacy Bulletin)

Compounded medication covered when commercial product unavailable and patient-specific medical necessity documented. Off-label use permitted with peer-reviewed evidence. Compounding pharmacy must meet USP standards.

How Aetna denies compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics — and how to counter it

Where Aetna pushes back: 1) Off-label use experimental; 2) Custom 4.5 mg LDN not commercially available — but plan considers naltrexone 50 mg tablet 'available'; 3) Plan exclusion.

Counter-arguments that hold up: LDN at 1.5–4.5 mg is mechanistically distinct from 50 mg naltrexone (low-dose endorphin / TLR4 modulation vs full opioid antagonism); commercial 50 mg tablet cannot be subdivided to 4.5 mg accurately. Cite Younger Pain Medicine 2013 (FM RCT), Cree Annals of Neurology 2010 (MS pilot), Smith Am J Gastroenterol 2007 (Crohn's), and additional published series. Off-label prescribing is legal and routinely covered when supported by peer-reviewed evidence. Submit pharmacy USP 795 attestation.

What Aetna typically denies for compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics treatments most often flagged for prior auth, step therapy, or medical necessity review:

• BHRT compounded
• Bi-Est cream
• Compounded testosterone
• Compounded progesterone
• Low-dose naltrexone (LDN)
• Compounded ketamine

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.